· Venture Capital Tracker · investment-strategies  · 1 min read

Mirage Raises $75M: AI Video Is Moving From Novelty to Throughput

Mirage's financing for Captions reflects demand for production-grade AI video workflows in marketing and creator operations.

Mirage (Captions) announced $75 million growth financing in 2026 (Undisclosed valuation).

The problem this startup is attacking

Video creation is still expensive and slow for teams that need high output across channels and geographies.

Why this is a live problem now

Short-form and paid social require constant iteration; AI tools now compete on reliability and workflow depth, not one-click effects.

Competitive map

Runway, Pika, Adobe Firefly video tools, and in-house post-production stacks.

Market signal (the number to remember)

  • Gartner forecasts global GenAI spending at $644B in 2025, up 76.4% YoY.

Practical takeaway (operator + investor)

If you are building in this category, optimize for measurable production outcomes (latency, reliability, unit economics, or risk reduction), not feature novelty. In 2026, capital is concentrating behind teams that can turn technical advantage into repeatable operating performance.

Sources

  1. Primary coverage: https://techcrunch.com/2026/03/24/mirage-raises-75m-to-continue-building-models-for-its-ai-video-editing-app-captions/
  2. Market data: https://www.gartner.com/en/newsroom/press-releases/2025-03-31-gartner-forecasts-worldwide-genai-spending-to-reach-644-billion-in-2025

By Venture Capital Tracker

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

Frequently Asked Questions

Common questions about this topic

Research the entities in this story

Persistent profiles connect this article to the companies and investors it discusses.

Back to Blog

Recommended next

Browse all research »

How Much Did AusperBio Raise? $120M Series C, No Valuation

AusperBio closed a $120 million Series C on August 27, 2026. An unnamed strategic investor led. RA Capital joined. The company cites $360 million raised since 2024. Valuation was not disclosed. AHB-137 is in Phase 3 in China and remains investigational.